In one paragraphArticle in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
14 authors.
Francesca CattoInstitute of Neuropathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-0429-2552 Ehsan Dadgar-KianiDepartment of Bioengineering, Stanford University, Stanford, California, United States of America.
Daniel KirschenbaumInstitute of Neuropathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Athena E EconomidesInstitute of Neuropathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0003-2340-6364 Anna Maria ReussInstitute of Neuropathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0003-1096-3030 Chiara TrevisanInstitute of Neuropathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-3997-094X Davide CaredioInstitute of Neuropathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-3723-894X Delic MirzetInstitute of Neuropathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Lukas FrickInstitute of Neuropathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Ulrike Weber-StadlbauerInstitute of Veterinary Pharmacology and Toxicology, University of Zurich, Zürich, Switzerland.
Sergey LitvinovComputational Science and Engineering Laboratory, School of Engineering and Applied Sciences, Harvard University, Cambridge, United States of America.
Petros KoumoutsakosComputational Science and Engineering Laboratory, School of Engineering and Applied Sciences, Harvard University, Cambridge, United States of America.
Jin Hyung LeeDepartment of Neurology and Neurological Sciences, Stanford University, California, United States of America.
Funding
From Optogenetic Functional MRI to Mechanogenetic Functional UltrasoundDP1NS116783 · NINDS · STANFORD UNIVERSITY · PI LEE, JIN HYUNG · 2019 to 2024
$5.5MInnovating high-resolution novel imaging approaches to elucidate mechanisms of prion-like spreadingof neurodegenerative diseaseR01AG064051 · NIA · STANFORD UNIVERSITY · PI GITLER, AARON D., LEE, JIN HYUNG · 2020 to 2024
$3.0MCRCNS: US-France-Israel Research Proposal: A personalized approach to brain stimulationR01EB030884 · NIBIB · STANFORD UNIVERSITY · PI LEE, JIN HYUNG · 2020 to 2024
$1.4MNIA NIH HHS R01 AG064051NIBIB NIH HHS R01 EB030884NINDS NIH HHS DP1 NS116783
6 · The paper itselfAbstract
A hallmark of Alzheimer's disease (AD) is the extracellular aggregation of toxic amyloid-beta (Aβ) peptides in form of plaques. Here, we identify netoglitazone, an antidiabetic compound previously tested in humans, as an Aβ aggregation antagonist. Netoglitazone improved cognition and reduced microglia activity in a mouse model of AD. Using quantitative whole-brain three-dimensional histology (Q3D), we precisely identified brain regions where netoglitazone reduced the number and size of Aβ plaques. We demonstrate the utility of Q3D in preclinical drug evaluation for AD by providing a high-resolution brain-wide view of drug efficacy. Applying Q3D has the potential to improve pre-clinical drug evaluation by providing information that can help identify mechanisms leading to brain region-specific drug efficacy.
Indexed as
Alzheimer DiseaseAmyloid beta-PeptidesHypoglycemic AgentsThiazolidinedionesAnimalsBrainDisease Models, AnimalHumansMiceMice, TransgenicMicrogliaPlaque, AmyloidAmyloid beta-PeptidesHypoglycemic AgentsThiazolidinediones
Identifiers
PMID40327707
PMCPMC12054868
What Socratic holds
Textmetadata
LicenceCC0
Read underepoch 390